Cardiovascular Diabetology
Papers 1791
1 page of 180 pages (1,791 results)
#2Maayan WaldmanH-Index: 6
Last.Michael AradH-Index: 28
view all 11 authors...
#1Salva reverentia Yurista (UMCG: University Medical Center Groningen)H-Index: 1
#2Herman H.W. Silljé (UMCG: University Medical Center Groningen)H-Index: 28
Last.B. D. Westenbrink (UMCG: University Medical Center Groningen)H-Index: 18
view all 5 authors...
While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of T2DM, particularly hypertension, may drive AF in the setting of T2DM. But direct mechanisms may also explain this relation, at least in part. In this regard, recent evidence suggests that mitochondrial dysfunction drives structural, electrical and contractile remodelling of atrial tissue in...
1 CitationsSource
#1Ayako Fuchigami (Toho University)H-Index: 1
#2Fumika Shigiyama (Toho University)H-Index: 3
Last.Hidenori YoshiiH-Index: 11
view all 12 authors...
Background Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagliflozin versus sitagliptin for modulating cardiometabolic risk factors including high glycated hemoglobin (HbA1c) levels, hypoglycemia, and body weight.
#1Hidekazu TanakaH-Index: 17
#2Fumitaka SogaH-Index: 3
Last.Ken-ichi HirataH-Index: 4
view all 11 authors...
#2Cheng Chieh LinH-Index: 42
Last.Tsai Chung LiH-Index: 33
view all 8 authors...
#1William A.E. Parker (University of Sheffield)H-Index: 4
#2Christian Schulte ('KCL': King's College London)H-Index: 6
Last.Ramzi Ajjan (University of Leeds)H-Index: 33
view all 9 authors...
Background Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional readout and biomarker kinetics in platelet activation and coagulation in patients with T2DM.
#1Samuel Seidu (Leicester General Hospital)H-Index: 10
#2Setor K. Kunutsor (UoB: University of Bristol)H-Index: 27
Last.Kamlesh Khunti (Leicester General Hospital)H-Index: 66
view all 7 authors...
The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular outcomes and all-cause mortality events in people with diabetes, we conducted an updated meta-analysis of published randomised controlled trials (RCTs) and a pooled analysis of individual participant data (IPD) from three trials. Randomised controlled trials of aspirin compared with pl...
#1Guillaume Besch (UFC: University of Franche-Comté)H-Index: 5
#2Sébastien Pili-Floury (UFC: University of Franche-Comté)H-Index: 10
Last.Romain ChopardFrancois (UFC: University of Franche-Comté)H-Index: 15
view all 13 authors...
Background Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation.
#1Lucia La SalaH-Index: 15
#2Simona Mrakic-Sposta (National Research Council)H-Index: 22
Last.Antonio CerielloH-Index: 76
view all 12 authors...
Background Impaired glucose tolerance (IGT) is a risk factor for the development of diabetes and related complications that ensue. Early identification of at-risk individuals might be beneficial to reduce or delay the progression of diabetes and its related complications. Recently, microRNAs emerged as potential biomarkers of diseases. The aim of the present study was to evaluate microRNA-21 as a potential biomarker for the risk of developing diabetes in adults with IGT and to investigate its do...
#1Aaron Y. Kluger (Baylor University)H-Index: 2
#2Kristen M. Tecson (A&M: Texas A&M University)H-Index: 4
Last.Peter A. McCulloughH-Index: 84
view all 8 authors...
To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and explore the potential determinants for their c...
2 CitationsSource
Top fields of study
Type 2 diabetes
Diabetes mellitus